Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Eledon (Nasdaq: ELDN) announced that Steven Perrin, Ph.D., President and Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 10:00 a.m. ET (7:00 a.m. PT).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Eledon (Nasdaq: ELDN) announced that Steven Perrin, Ph.D., President and Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 10:00 a.m. ET (7:00 a.m. PT).
According to the company, the session will be webcast live with a replay available afterward on Eledon’s website under Events.
Details
News Market Reaction – ELDN
On Feb 6, the first trading day after this news, ELDN closed 11.17% above the previous close.
Data tracked by StockTitan Argus for the Feb 6 session.
Key Figures
- Summit date
- February 12, 2026
- Date of Guggenheim Emerging Outlook: Biotech Summit 2026 participation
- Fireside chat time
- 10:00 a.m. ET (7:00 a.m. PT)
- Scheduled time for ELDN’s fireside chat at the summit
Historical Context
-
Long-term Phase 1b tegoprubart kidney transplant data with favorable safety and eGFR.
-
2025 progress, 2026 tegoprubart outlook, and financing expected to fund into 2Q 2027.
-
Announcement of participation in the 37th Annual Piper Sandler Healthcare Conference.
-
Preliminary tegoprubart data in islet transplant showing insulin independence with no major toxicities.
-
Q3 2025 results, BESTOW Phase 2 data, and $57.5M equity financing for programs.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steven Perrin, Ph.D., President and Chief Scientific Officer will participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 10:00 a.m. ET (7:00 a.m. PT).
To register in advance for the fireside chat webcast, sign up here.
A webcast replay will be accessible following the live session on the Company’s website under Events.
About Eledon Pharmaceuticals and tegoprubart
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.
Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter
Investor Contact:
Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com
Media Contact:
Jenna Urban
CG Life
(212) 253 8881
jurban@cglife.com
Source: Eledon Pharmaceuticals
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.